Journal of Medicinal Chemistry · 2021 · 41 citations · 53 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructural BiologyCovalent Inhibitor DesignLigand BindingPeptide Drug DiscoveryPeptidomimetic DesignProtein DesignProtein StructureCovalent InhibitorsLysine-targeted InhibitorsPro-apoptotic AgentsPro-apoptotic ProteinsProtein TargetsProtein-protein Interaction Inhibitor DesignProtein-protein Interaction Inhibitor DiscoveryTargeted Covalent Inhibitors
Modulating disease-relevant protein-protein interactions (PPIs) using pharmacological tools is a critical step toward the design of novel therapeutic strategies. Over the years, however, targeting PPIs has proven a very challenging task owing to the large interfacial areas. Our recent efforts identified possible novel routes for the design of potent and selective inhibitors of PPIs using a structure-based design of covalent inhibitors targeting Lys residues. In this present study, we report on the design, synthesis, and characterizations of the first Lys-covalent BH3 peptide that has a remarkable affinity and selectivity for hMcl-1 over the closely related hBfl-1 protein. Our structural studies, aided by X-ray crystallography, provide atomic-level details of the inhibitor interactions that can be used to further translate these discoveries into novel generation, Lys-covalent pro-apoptotic agents.
53
<i>Phaser</i>crystallographic software
Airlie J. McCoy, Ralf W. Grosse‐Kunstleve, Paul D. Adams et al. · Journal of Applied Crystallography · 2007 · 20.9K citations · Full text
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Daniel Martinez Molina, Rozbeh Jafari, Marina Ignatushchenko et al. · Science · 2013 · 2.2K citations
Medicine, Oncology, Pharmacology +17